EGFR and non-small cell lung carcinoma: Although EGFR tyrosine kinase inhibitors (EGFR‐TKIs) have become the recommended treatment strategy for patients with NSCLC harboring EGFR mutations, resistance would eventually occur with progression‐free survival (PFS) durations of 9.5–13.1 months for those treated with first‐ or second‐generation EGFR‐TKIs and 18.9 months for those treated with osimertinib.6, 7, 8, 9